Summary: Catalent has successfully addressed the challenges associated with plasmid DNA manufacturing by developing robust process and analytical platforms. Catalent’s approach involves a one-process-fits-all single-use (SU) manufacturing process in compliance with current good manufacturing practices (cGMP) standards.

Summary: Catalent offers extensive expertise in the bioproduction of plasmid DNA, from early stages of development to CGMP manufacturing to satisfy clinical and commercial needs.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

Summary: Watch this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimized...

Summary: Discover how a platform process for the manufacturing of plasmid DNA is helpful for all stages, from screening candidates in preclinical studies to large-scale production for late-stage and commercial needs.

Summary: Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.

Summary: Plasmid DNA is a critical raw material for cell and gene therapies. Discover the importance of having an integrated partner like Catalent Cell & Gene, and how we can keep your development and manufacturing on track and on schedule.

Summary: The Catalent team has broad expertise in developing customized plasmid DNA manufacturing solutions, from plasmid engineering to large-scale GMP plasmid production.

Summary: Learn how Catalent Cell & Gene Therapy recognizes the challenges faced when obtaining raw materials, and how our investments in pDNA manufacturing secure our integrated supply chain.